The impact of omega-3 polyunsaturated fatty acid supplementation on the incidence of cardiovascular events and complications in peripheral arterial disease: a systematic review and meta-analysis

BMC Cardiovascular Disorders

Carla G Taylor¹  Peter Zahradka¹  Carol Friesen³  Ahmed M Abou-Setta⁴  Ryan Zarychanski⁴  Azadeh Yeganeh²  Jennifer E Enns² 

[1] Department of Human Nutritional Sciences, University of Manitoba, Winnipeg, Canada;Canadian Centre for Agri-Food Research in Health and Medicine, St. Boniface Research Centre, R2019-351 Taché Ave, Winnipeg R2H 2A6, Canada;Neil John Maclean Health Sciences Library, University of Manitoba Libraries, 770 Bannatyne Ave, Winnipeg R3E 0W3, Canada;George & Fay Yee Centre for Healthcare Innovation/Winnipeg Regional Health Authority, Health Sciences Centre, University of Manitoba, 820 Sherbrook St, Winnipeg R3T 2N2, Canada

关键词: Intermittent claudication;    Peripheral arterial disease;    Omega-3 polyunsaturated fatty acid;   

Others  :  854713
DOI  :  10.1186/1471-2261-14-70

 received in 2014-03-17, accepted in 2014-05-28,  发布年份 2014

【 摘 要 】

Background

Individuals with peripheral arterial disease are at higher risk for cardiovascular events than the general population. While supplementation with omega-3 polyunsaturated fatty acids (PUFA) has been shown to improve vascular function, it remains unclear if supplementation decreases serious clinical outcomes. We conducted a systematic review and meta-analysis to determine whether omega-3 PUFA supplementation reduces the incidence of cardiovascular events and complications in adults with peripheral arterial disease.

Methods

We searched five electronic databases (MEDLINE, EMBASE, CENTRAL, Scopus and the International Clinical Trials Registry Platform) from inception to 6 December 2013 to identify randomized trials of omega-3 PUFA supplementation (from fish or plant oils) that lasted ≥12 weeks in adults with peripheral arterial disease. No language filters were applied. Data on trial design, population characteristics, and health outcomes were extracted. The primary outcome was major adverse cardiac events; secondary outcomes included myocardial infarction, cardiovascular death, stroke, angina, amputation, revascularization procedures, maximum and pain-free walking distance, adverse effects of the intervention, and quality of life. Trial quality was assessed using the Cochrane Risk of Bias tool.

Results

Of 741 citations reviewed, we included five trials enrolling 396 individuals. All included trials were of unclear or high risk of bias. There was no evidence of a protective association of omega-3 PUFA supplementation against major adverse cardiac events (pooled risk ratio 0.73, 95% CI 0.22 to 2.41, I² 75%, 2 trials, 288 individuals) or other serious clinical outcomes. Adverse events and compliance were poorly reported.

Conclusions

Our results showed that insufficient evidence exists to suggest a beneficial effect of omega-3 PUFA supplementation in adults with peripheral arterial disease with regard to cardiovascular events and other serious clinical outcomes.

【 授权许可】

   
2014 Enns et al.; licensee BioMed Central Ltd.

【 图 表 】

【 参考文献 】

• [1]What is peripheral arterial disease? http://www.nhlbi.nih.gov/health/health-topics/topics/pad/ webcite
• [2]Dobesh PP, Stacy ZA, Persson EL: Pharmacologic therapy for intermittent claudication. Pharmacotherapy 2009, 29(5):526-553.
• [3]Pande RL, Perlstein TS, Beckman JA, Creager MA: Secondary prevention and mortality in peripheral artery disease: National Health and Nutrition Examination Study, 1999 to 2004. Circulation 2011, 124(1):17-23.
• [4]Leng GC, Papacosta O, Whincup P, Wannamethee G, Walker M, Ebrahim S, Nicolaides AN, Dhanjil S, Griffin M, Belcaro G, Rumley A, Lowe GD: Femoral atherosclerosis in an older British population: prevalence and risk factors. Atherosclerosis 2000, 152(1):167-174.
• [5]Norgren L, Hiatt WR, Dormandy JA, Nehler MR, Harris KA, Fowkes FG, TASC II Working Group: Inter-society consensus for the management of peripheral arterial disease (TASC II). J Vasc Surg 2007, 45((Suppl S)):S5-S67.
• [6]Mozaffarian D, Wu JH: Omega-3 fatty acids and cardiovascular disease: effects on risk factors, molecular pathways, and clinical events. J Am Coll Cardiol 2011, 58(20):2047-2067.
• [7]Harris WS, Miller M, Tighe AP, Davidson MH, Schaefer EJ: Omega-3 fatty acids and coronary heart disease risk: clinical and mechanistic perspectives. Atherosclerosis 2008, 197(1):12-24.
• [8]Calder PC: Polyunsaturated fatty acids and inflammatory processes: new twists in an old tale. Biochimie 2009, 91(6):791-795.
• [9]Bucher HC, Hengstler P, Schindler C, Meier G: N-3 polyunsaturated fatty acids in coronary heart disease: a meta-analysis of randomized controlled trials. Am J Med 2002, 112(4):298-304.
• [10]Mozaffarian D, Rimm EB: Fish intake, contaminants, and human health: evaluating the risks and the benefits. JAMA 2006, 296(15):1885-1899.
• [11]Marik PE, Varon J: Omega-3 dietary supplements and the risk of cardiovascular events: a systematic review. Clin Cardiol 2009, 32(7):365-372.
• [12]Leon H, Shibata MC, Sivakumaran S, Dorgan M, Chatterley T, Tsuyuki RT: Effect of fish oil on arrhythmias and mortality: systematic review. BMJ 2008, 337:a2931.
• [13]Mente A, de Koning L, Shannon HS, Anand SS: A systematic review of the evidence supporting a causal link between dietary factors and coronary heart disease. Arch Intern Med 2009, 169(7):659-669.
• [14]Delgado-Lista J, Perez-Martinez P, Lopez-Miranda J, Perez-Jimenez F: Long chain omega-3 fatty acids and cardiovascular disease: a systematic review. Br J Nutr 2012, 107(Suppl 2):S201-S213.
• [15]Zhao YT, Chen Q, Sun YX, Li XB, Zhang P, Xu Y, Guo JH: Prevention of sudden cardiac death with omega-3 fatty acids in patients with coronary heart disease: a meta-analysis of randomized controlled trials. Ann Med 2009, 41(4):301-310.
• [16]Filion KB, El Khoury F, Bielinski M, Schiller I, Dendukuri N, Brophy JM: Omega-3 fatty acids in high-risk cardiovascular patients: a meta-analysis of randomized controlled trials. BMC Cardiovasc Disord 2010, 10:24-2261-10-24.
• [17]Chen Q, Cheng LQ, Xiao TH, Zhang YX, Zhu M, Zhang R, Li K, Wang Y, Li Y: Effects of omega-3 fatty acid for sudden cardiac death prevention in patients with cardiovascular disease: a contemporary meta-analysis of randomized, controlled trials. Cardiovasc Drugs Ther 2011, 25(3):259-265.
• [18]Effects of eicosapentaenoic acid and docosahexaenoic acid on mortalty across diverse settings: systematic review and meta-analysis of randomized trials and prospective cohorts 2012. http://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0041092/ webcite
• [19]Hooper L, Thompson RL, Harrison RA, Summerbell CD, Ness AR, Moore HJ, Worthington HV, Durrington PN, Higgins JP, Capps NE, Riemersma RA, Ebrahim SB, Davey Smith G: Risks and benefits of omega 3 fats for mortality, cardiovascular disease, and cancer: systematic review. BMJ 2006, 332(7544):752-760.
• [20]Kwak SM, Myung SK, Lee YJ, Seo HG, Korean Meta-analysis Study Group: Efficacy of omega-3 fatty acid supplements (eicosapentaenoic acid and docosahexaenoic acid) in the secondary prevention of cardiovascular disease: a meta-analysis of randomized, double-blind, placebo-controlled trials. Arch Intern Med 2012, 172(9):686-694.
• [21]Rizos EC, Ntzani EE, Bika E, Kostapanos MS, Elisaf MS: Association between omega-3 fatty acid supplementation and risk of major cardiovascular disease events: a systematic review and meta-analysis. JAMA 2012, 308(10):1024-1033.
• [22]Sprengers RW, Janssen KJ, Moll FL, Verhaar MC, van der Graaf Y, SMART Study Group: Prediction rule for cardiovascular events and mortality in peripheral arterial disease patients: data from the prospective Second Manifestations of ARTerial disease (SMART) cohort study. J Vasc Surg 2009, 50(6):1369-1376.
• [23]West SG, Krick AL, Klein LC, Zhao G, Wojtowicz TF, McGuiness M, Bagshaw DM, Wagner P, Ceballos RM, Holub BJ, Kris-Etherton PM: Effects of diets high in walnuts and flax oil on hemodynamic responses to stress and vascular endothelial function. J Am Coll Nutr 2010, 29(6):595-603.
• [24]Schiano V, Laurenzano E, Brevetti G, De Maio JI, Lanero S, Scopacasa F, Chiariello M: Omega-3 polyunsaturated fatty acid in peripheral arterial disease: effect on lipid pattern, disease severity, inflammation profile, and endothelial function. Clin Nutr 2008, 27(2):241-247.
• [25]Woodcock BE, Smith E, Lambert WH, Jones WM, Galloway JH, Greaves M, Preston FE: Beneficial effect of fish oil on blood viscosity in peripheral vascular disease. Br Med J (Clin Res Ed) 1984, 288(6417):592-594.
• [26]Madden J, Shearman CP, Dunn RL, Dastur ND, Tan RM, Nash GB, Rainger GE, Brunner A, Calder PC, Grimble RF: Altered monocyte CD44 expression in peripheral arterial disease is corrected by fish oil supplementation. Nutr Metab Cardiovasc Dis 2009, 19(4):247-252.
• [27]PROSPERO International prospective register of systematic reviews http://www.crd.york.ac.uk/PROSPERO/display_record.asp?ID=CRD42013005488#.U5dUD_ldV0I webcite
• [28]Cochrane handbook for systematic reviews of interventions http://www.cochrane-handbook.org webcite
• [29]Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gotzsche PC, Ioannidis JP, Clarke M, Devereaux PJ, Kleijnen J, Moher D: The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. J Clin Epidemiol 2009, 62(10):e1-e34.
• [30]Hodson L, Eyles HC, McLachlan KJ, Bell ML, Green TJ, Skeaff CM: Plasma and erythrocyte fatty acids reflect intakes of saturated and n-6 PUFA within a similar time frame. J Nutr 2014, 144(1):33-41.
• [31]Higgins JP, Altman DG, Gotzsche PC, Juni P, Moher D, Oxman AD, Savovic J, Schulz KF, Weeks L, Sterne JA, Cochrane Bias Methods Group: The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. BMJ 2011, 343:d5928.
• [32]Bradburn MJ, Deeks JJ, Berlin JA, Russell Localio A: Much ado about nothing: a comparison of the performance of meta-analytical methods with rare events. Stat Med 2007, 26(1):53-77.
• [33]Higgins JP, Thompson SG: Quantifying heterogeneity in a meta-analysis. Stat Med 2002, 21(11):1539-1558.
• [34]Leng GC, Lee AJ, Fowkes FG, Jepson RG, Lowe GD, Skinner ER, Mowat BF: Randomized controlled trial of gamma-linolenic acid and eicosapentaenoic acid in peripheral arterial disease. Clin Nutr 1998, 17(6):265-271.
• [35]Carrero JJ, Lopez-Huertas E, Salmeron LM, Baro L, Ros E: Daily supplementation with (n-3) PUFAs, oleic acid, folic acid, and vitamins B-6 and E increases pain-free walking distance and improves risk factors in men with peripheral vascular disease. J Nutr 2005, 135(6):1393-1399.
• [36]Carrero JJ, López-Huertas E, Salmerón LM, Ramos VE, Baró L, Ros E: Simvastatin and supplementation with ω-3 polyunsaturated fatty acids and vitamins improves claudication distance in a randomized PILOT study in patients with peripheral vascular disease. Nutr Res 2006, 26(12):637-643.
• [37]Gans RO, Bilo HJ, Weersink EG, Rauwerda JA, Fonk T, Popp-Snijders C, Donker AJ: Fish oil supplementation in patients with stable claudication. Am J Surg 1990, 160(5):490-495.
• [38]Ishikawa Y, Yokoyama M, Saito Y, Matsuzaki M, Origasa H, Oikawa S, Sasaki J, Hishida H, Itakura H, Kita T, Kitabatake A, Nakaya N, Sakata T, Shimada K, Shirato K, Matsuzawa Y, JELIS Investigators: Preventive effects of eicosapentaenoic acid on coronary artery disease in patients with peripheral artery disease. Circ J 2010, 74(7):1451-1457.
• [39]Pan A, Chen M, Chowdhury R, Wu JH, Sun Q, Campos H, Mozaffarian D, Hu FB: alpha-Linolenic acid and risk of cardiovascular disease: a systematic review and meta-analysis. Am J Clin Nutr 2012, 96(6):1262-1273.
• [40]Chowdhury R, Stevens S, Gorman D, Pan A, Warnakula S, Chowdhury S, Ward H, Johnson L, Crowe F, Hu FB, Franco OH: Association between fish consumption, long chain omega 3 fatty acids, and risk of cerebrovascular disease: systematic review and meta-analysis. BMJ 2012, 345:e6698.
• [41]Cao H, Wang X, Huang H, Ying SZ, Gu YW, Wang T, Huang CX: Omega-3 fatty acids in the prevention of atrial fibrillation recurrences after cardioversion: a meta-analysis of randomized controlled trials. Intern Med 2012, 51(18):2503-2508.
• [42]He Z, Yang L, Tian J, Yang K, Wu J, Yao Y: Efficacy and safety of omega-3 fatty acids for the prevention of atrial fibrillation: a meta-analysis. Can J Cardiol 2013, 29(2):196-203.
• [43]Kromhout D, de Goede J: Update on cardiometabolic health effects of omega-3 fatty acids. Curr Opin Lipidol 2014, 25(1):85-90.
• [44]Pase MP, Grima NA, Sarris J: Do long-chain n-3 fatty acids reduce arterial stiffness? A meta-analysis of randomised controlled trials. Br J Nutr 2011, 106(7):974-980.
• [45]Iso H, Kobayashi M, Ishihara J, Sasaki S, Okada K, Kita Y, Kokubo Y, Tsugane S, JPHC Study Group: Intake of fish and n3 fatty acids and risk of coronary heart disease among Japanese: the Japan Public Health Center-Based (JPHC) Study Cohort I. Circulation 2006, 113(2):195-202.
• [46]Kobayashi M, Sasaki S, Kawabata T, Hasegawa K, Tsugane S, JPHC: Validity of a self-administered food frequency questionnaire used in the 5-year follow-up survey of the JPHC Study Cohort I to assess fatty acid intake: comparison with dietary records and serum phospholipid level. J Epidemiol 2003, 13(1 Suppl):S64-S81.
• [47]LaRosa JC, He J, Vupputuri S: Effect of statins on risk of coronary disease: a meta-analysis of randomized controlled trials. JAMA 1999, 282(24):2340-2346.
• [48]Joint FAO/WHO Expert Consultation on Fats and Fatty Acids in Human Nutrition: Interim Summary of Conclusions and Dietary Recommendations on Total Fat & Fatty Acids. http://www.who.int/nutrition/topics/FFA_interim_recommendations/en/ webcite
• [49]De Caterina R: N-3 fatty acids in cardiovascular disease. N Engl J Med 2011, 364(25):2439-2450.
• [50]Campbell A, Price J, Hiatt WR: Omega-3 fatty acids for intermittent claudication. Cochrane Database Syst Rev 2013, 7:CD003833.